[PDF] Top 20 The Changing Face of Multiple Sclerosis and Disease-modifying Therapies
Has 10000 "The Changing Face of Multiple Sclerosis and Disease-modifying Therapies" found on our website. Below are the top 20 most common "The Changing Face of Multiple Sclerosis and Disease-modifying Therapies".
The Changing Face of Multiple Sclerosis and Disease-modifying Therapies
... The treating physician’s responsibility is to educate the patient on the class I clinical trials, the EBM reviews of treatment, potential tolerability and safety issues as well as the physician’s clinical perspective and ... See full document
6
<p>Managing Disease-Modifying Therapies and Breakthrough Activity in Multiple Sclerosis Patients During the COVID-19 Pandemic: Toward an Optimized Approach</p>
... with multiple sclerosis (pwMS) seem to be at higher risk of infection compared with the general population, 10 and constitute a susceptible population for contracting COVID-19 and frequently devel- oping ... See full document
12
Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis
... Purpose: To evaluate adherence to disease-modifying therapies (DMTs) among patients with multiple sclerosis (MS) initiating oral and injectable DMTs, and to estimate the impact of adh[r] ... See full document
10
Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology
... summary: Disease-modifying therapies for adults with multiple sclerosis,” Rae-Grant et ...stopping disease-modifying therapies for clinically isolated syndrome, ... See full document
7
Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: a discrete choice experiment
... Table 4 and Figure 1 show the results of the mixed logit of patient preferences for DMTs. To obtain the partial utilities (preference scores expressed as odds ratios [ORs]) for levels within the attributes, beta ... See full document
12
The effect of disease modifying therapies on disability progression in multiple sclerosis: A systematic overview of meta analyses
... One author (SC) extracted information on the citation details, objective, study design, participant details, search details, inclusion criteria, interventions, and outcomes, including quality assessment instrument, from ... See full document
25
Effects of disease modifying therapies on brain and grey matter atrophy in relapsing remitting multiple sclerosis
... In the two Phase III studies FREEDOMS and FREE- DOMS II [106, 107], fingolimod was found to reduce the PBV loss in RRMS patients by 36% (p < 0.001) and 33% (p = 0.0002), respectively. Whether this effect on PBV was ... See full document
10
Psychosocial predictors of patient adherence to disease-modifying therapies for multiple sclerosis
... clinical outcomes for existing disease states are major areas of interest for the journal. This journal has been accepted for indexing on PubMed Central. The manuscript management system is completely online and ... See full document
6
The prevalence of injection-site reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study
... 4 disease-modifying therapies (DMTs) for at least 2 years prior to enrollment: IM IFN b -1a (Avo- nex ® ), SC IFN b -1b (Betaseron ® /Betaferon ® ), SC IFN b - 1a (Rebif ® ), or SC GA (Copaxone ® ... See full document
7
Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis
... onset or diagnosis of MS, which could provide insight into the progression and severity of patients’ MS. We measured some proxies of MS severity, such as baseline corticosteroid use, but we did not have access to other ... See full document
12
Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001–2010
... switching therapies increased with duration of follow-up while the proportion discontinuing DMT increased from 12 months to 24 months but declined after 36 ... See full document
8
Adherence to disease-modifying therapies in patients with multiple sclerosis
... Purpose: The main purpose of this study was to examine adherence to first-line disease- modifying therapy (DMT) in MS patients using the self-report Multiple Sclerosis Trea[r] ... See full document
10
Disease-modifying therapies in relapsing–remitting multiple sclerosis
... It has been hypothesized that the efficacy of IFN could be higher if it is used at the first appearance of symptoms, in Clinically Isolated Syndromes suggestive of demyelinating events, a pathology which carries a high ... See full document
9
Cost of disease-modifying therapies for multiple sclerosisAbout multiple sclerosis
... WHAT ARE MS “ DISEASE-MODIFYING THERAPIES ” ? DMTs are drugs that alter the natural course of MS. They reduce the frequency and severity of attacks, reduce new brain lesions, and slow the development ... See full document
6
Persistence to disease-modifying therapies for multiple sclerosis in a Canadian cohort
... these therapies may still occur due to safety considerations or the thresholds which need to be met to qualify for access to second-line ...additional therapies continue to emerge, factors associated with ... See full document
9
WHY IS PRIMARY CARE IMPORTANT?
... Injectable disease-modifying therapy for RRMS: A review of adherence ...to disease modifying therapies in MS: Utility of the health beliefs ...model. Multiple Sclerosis, ... See full document
22
Development and usability testing of a patient decision aid for newly diagnosed relapsing multiple sclerosis patients
... Multiple sclerosis (MS) is a leading cause of non-trau- matic neurological disability for young adults ...relapsing-remitting multiple sclerosis (RRMS) and ex- perience clearly defined ... See full document
11
Comprehensive systematic review summary: Disease-modifying therapies for adults with multiple sclerosisReport of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology
... summary: Disease-modifying therapies for adults with multiple sclerosis,” Rae-Grant et ...stopping disease-modifying therapies for clinically isolated syndrome, ... See full document
19
The short and long-term effects of pregnancy on multiple sclerosis and experimental autoimmune encephalomyelitis
... However, although pregnancy is protective against relapses, the rate of relapse is not zero. Furthermore, in more recent studies there have been reports of relapses during pregnancy, possibly due to a rebound effect ... See full document
27
Emerging therapies for treatment of multiple sclerosis
... immune-based therapies have been developed and tested in patients with multiple ...these therapies are showing a high level of efficacy, with an acceptable adverse effect ...present therapies ... See full document
7
Related subjects